
Vehicle
Tumor Volume (mm³)
4000.00
3000.00
2000.00
1000.00
0.00
10 13 17 19 24 27 31 34 39 41 46 48 52 55 59

FIG. 1A



50uCi Once
3000.00
2000.00
1000.00
0.00
Tumor Volume (mm³)
10 13 17 19 24 27 31 34 39 41 46 48 52 55 59

FIG. 1B



50uCi Multi
Tumor Volume (mm³)
3000.00
2000.00
1000.00
0.00
10 13 17 19 24 27 31 34 39 41 46 48 52 55 59

FIG. 1C



100uCi Once
Tumor Volume (mm³)
3000.00
2000.00
1000.00
0.00
10 13 17 19 24 27 31 34 39 41 46 48 52 55 59

FIG. 1D



Bortezomib
Tumor Volume (mm³)
3000.00
2000.00
1000.00
0.00
10 13 17 19 24 27 31 34 39 41 46 48 52 55 59

FIG. 1E



Tumor Volume (mm³)
2,000
1,750
1,500
1,250
1,000
750
500
250
0
0
10
20
30
40
50
60
Study Days
Vehicle
50µCi once
50µCi x 2
100µCi once
Bortezomid

FIG. 2



100%
80%
60%
40%
20%
0%
23
28
33
38
43
48
53
58
63
68
73
Vehicle
CLR 131 50µCi 1
CLR 131 50µCi Multidose
CLR 131 100µCi 1
Bortezomib

FIG. 3



Change in Mean Body Weight (%)
10
5
0
-5
-10
10
13
19
24
26
34
39
41
46
52
55
59

FIG. 4

	Time to Reach 900mm^3	Tumor Volume Doubling Time
Control	35	8.24
CLR 131 50x1	51	18.50
CLR 131 50x2	74	58.02
CLR 131 100x1	54	28.21
Bortezomib	64	30.05

FIG. 5



Fractionated Dosing of CLR 131 OPM-2 Model
Tumor Volume (mm²)
2000.00
1800.00
1600.00
1400.00
1200.00
1000.00
800.00
600.00
400.00
200.00
0.00
10 13 17 19 24 27 31 34 39 41 46 48 52 55 59 62 66
CLR 131 Day 1 and 8
Vehicle
CLR 131 Day 1 and 4
CLR 131 Day 1 and 5
CLR 131 Days 1 and 9
CLR 131 Day 1 and 6
CLR 131 Day 1, 5, and 8

FIG. 6



Dose 1 Dose 2
(Day 1) (Day 15)
Dose 3 Dose 4
(Day 1)(Day 15)
Cycle 1
Cycle 2
Second Cycle to begin on
Study Days 57-180 (from day 1):
Delay from day 57 for start of dose 3 can be due to any medical reason necessitates such delay

FIG. 7